Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade

Ho, Shinn‐Ying; Hsu, Chia Yang; Liu, Po Hong; Ko, Chih Chieh; Huang, Yi Hsiang; Su, Chien Wei; Lee, Rheun‐Chuan; Hou, Ming; Huo, Teh Ia

doi:10.3390/cancers12051130

Cited by 10 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CTP classification and MELD score are used to evaluate the severity of liver injury. However, these two models were reported to have some shortcomings 28 . Recently, ALBI grade is a simple and objective indicator to assess the severity of liver damage in HCC patients and has been validated by several research groups 18,19 .…”

Section: Discussionmentioning

confidence: 99%

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Liu

Hsu

et al. 2021

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aim Size and number are major determinants of tumor burden in hepatocellular carcinoma (HCC). Patients with HCC undergoing transarterial chemoembolization (TACE) have variable outcomes due to heterogeneity of tumor burden. Recently, tumor burden score (TBS) was proposed to evaluate the extent of tumor involvement. However, the prognostic accuracy of TBS has not been well evaluated in HCC. This study aimed to assess its prognostic role in HCC patients undergoing TACE. Methods A total of 935 treatment‐naïve HCC patients receiving TACE were retrospectively analyzed. Multivariate Cox proportional hazards model was used to determine independent prognostic predictors. Results Tumor burden score tended to increase with increasing size and number of tumors in study patients. The Cox model showed that serum creatinine ≥ 1.2 mg/dL (hazard ratio [HR]: 1.296, 95% confidence interval [CI]: 1.077–1.559, P = 0.006), serum α‐fetoprotein ≥ 400 ng/dL (HR: 2.245, 95% CI: 1.905–2.645, P < 0.001), vascular invasion (HR: 1.870, 95% CI: 1.520–2.301, P < 0.001), medium TBS (HR: 1.489, 95% CI: 1.206–1.839, P < 0.001) and high TBS (HR: 2.563, 95% CI: 1.823–3.602, P < 0.001), albumin–bilirubin (ALBI) grade 2–3 (HR: 1.521, 95% CI: 1.291–1.792, P < 0.001), and performance status 1 (HR: 1.362, 95% CI: 1.127–1.647, P < 0.001) and status 2 (HR: 1.553, 95% CI: 1.237–1.948, P < 0.001) were associated with increased mortality. Patients with high TBS had poor overall survival in Barcelona Clinic Liver Cancer stage B/C and different ALBI grades. Conclusions Tumor burden score is a feasible new prognostic surrogate marker of tumor burden in HCC and can well discriminate survival in patients undergoing TACE across different baseline characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Liu

Hsu

et al. 2021

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ALBI score is calculated using the following equation as previously defined: 11,13,22 ALBI score = 0.66 � log 10 bilirubin (μmol/L) − 0.085 � albumin (g/L).…”

Section: Albumin-bilirubin Score and Gradingmentioning

confidence: 99%

Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma

Liu

Hsu

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Background: Liver functional reserve is a major prognostic determinant in patients with hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score is an objective method to assess the severity of cirrhosis in this setting. However, calculation of the ALBI score is complex and difficult to access in clinical practice.Recently, the EZ (easy)-ALBI score was proposed as an alternative biomarker of liver injury. We aimed to evaluate the prognostic role of the EZ-ALBI score in HCC from early to advanced stages.Methods: A total of 3794 newly diagnosed HCC patients were prospectively enrolled and retrospectively analyzed. Independent prognostic predictors were determined by using the multivariate Cox proportional hazards model. Results:The EZ-ALBI score showed good correlation with the ALBI score (correlation coefficient, 0.965; p < 0.001). The correlation of the EZ-ALBI score was highly preserved in different Child-Turcotte-Pugh (CTP) classifications, treatment methods, and Barcelona Clinic Liver Cancer (BCLC) stages (correlation coefficients, 0.90-0.97). In the Cox multivariate analysis, age >65 years, male sex, serum α-fetoprotein >20 ng/ml, large or multiple tumors, total tumor volume >100 cm 3 , vascular invasion or distant metastasis, ascites, poor performance status, EZ-ALBI grade 2 and 3, and noncurative treatments were independently associated with increased mortality (all p < 0.05). Moreover, EZ-ALBI grade can stratify long-term survival in patients with different CTP class, treatment strategy, and BCLC stage. Conclusions:The EZ-ALBI score is an easy and feasible method to evaluate liver functional reserve. As a new prognostic biomarker in HCC, the predictive power of the EZ-ALBI grade is independent across different cancer stages and treatments.

show abstract

“… 21 , 22 In addition, several epidemiological surveys and experimental studies have shown that the risk of death from HCC was significantly associated with mass size, the number of masses, macrovascular invasion, and intrahepatic metastases; thus, suggesting that hepatocarcinogenesis is influenced by genetic factors. 23–25 …”

Section: Current Status Of Liver Cancer Treatmentmentioning

confidence: 99%

Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer

Zhang

et al. 2022

IJN

View full text Add to dashboard Cite

The mortality rate of liver cancer is gradually increasing worldwide due to the increasing risk factors such as fatty liver, diabetes, and alcoholic cirrhosis. The diagnostic methods of liver cancer include ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), among others. The treatment of liver cancer includes surgical resection, transplantation, ablation, and chemoembolization; however, treatment still faces multiple challenges due to its insidious development, high rate of recurrence after surgical resection, and high failure rate of transplantation. The emergence of liposomes has provided new insights into the treatment of liver cancer. Due to their excellent carrier properties and maneuverability, liposomes can be used to perform a variety of functions such as aiding in imaging diagnoses, combinatorial therapies, and integrating disease diagnosis and treatment. In this paper, we further discuss such advantages.

show abstract

Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade

Cited by 10 publications

References 38 publications

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization

Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma

Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer

Contact Info

Product

Resources

About